biocrea gmbh logo

BioCrea GmbH

BioCrea GmbH develops drugs to treat debilitating central nervous system diseases. The company primarily focuses on developing programs focusing on neurological and psychotic disorders.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.biocrea.com
Founded2010
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Meissner Strasse 191Radebeul, 01445
Radebeul
Germany
Email
Contact Number
49 351 40 430

It is in collaboration with the Department of Neurology at Dresden University of Technology to discover new treatments for neurodegenerative disorders such as Amyotrophic Lateral Sclerosis.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/biocrea-gmbh” connections=”true” suffix=””]

BioCrea discovery platform projects include NMDA-receptor positive & negative allosteric modulator (PAM & NAM) to treat depression and schizophrenia, and selective GABA receptor modulators to treat epilepsy and autism spectrum disorders.

In Feb 2012, entered into an asset purchase agreement with Boehringer Ingelheim, under which it granted worldwide development & commercialization rights of certain PDE platform research programs, including its PDE2 inhibitor, BCA909.